We selected both ASDAI-CRP and BASDAI-CRP as clinical remission criteria because BASDAI incorporates additional clinical outcomes of interest, such as physical function; assesses enthesopathy; and has both eligibility criterion and outcome in clinical trials [9]. This evidence concerns the gene CRP and enthesopathy.